Most of the conditions on this page have the same upstream problem: the blood isn't getting where it needs to go.
Endothelial dysfunction — the failure of blood vessel walls to regulate flow, respond to demand, and maintain structural integrity — is now understood to be a central mechanism in heart disease, cognitive decline, erectile dysfunction, diabetic complications, and a growing list of other conditions.
EECP doesn't treat these conditions directly. It treats the vascular environment that underlies them. That's why the same therapy produces meaningful results across such a wide range of diagnoses.
Three things EECP does that matter across all of these conditions
- Diastolic augmentationIncreases coronary perfusion pressure by up to 80% during each session — more blood to the heart muscle when it's most receptive.
- Endothelial upregulationSustained shear stress on vessel walls triggers nitric oxide production, reducing inflammation and improving vascular tone.
- Collateral developmentOver 35 sessions, the body responds by growing new collateral vessels — a biological bypass that persists for 12 to 18 months.
The evidence base, and how we think about each one.
Chronic & Refractory Angina
Chronic stable angina is the condition EECP was originally developed for, and it remains the strongest evidence base. The International EECP Patient Registry — over 5,000 patients — showed 78% reported reduced angina frequency, 74% improved to a lower CCS class, and 73% reduced or eliminated nitroglycerin use.
For refractory angina — patients who continue to have chest pain despite maximal medical therapy, stents, or bypass surgery — EECP is one of the few options with a meaningful evidence base. The ACC/AHA guidelines list it as a Class IIb recommendation for this population.
We operate cash-pay and do not accept insurance reimbursement. Medicare formally covers EECP for chronic stable angina under NCD 20.20, and patients may submit our documentation for self-reimbursement.
International EECP Patient Registry (n=5,000+). ACC/AHA Class IIb recommendation for refractory angina. Medicare NCD 20.20 coverage for chronic stable angina.
Ischemic Heart Failure
The PEECH trial (Prospective Evaluation of EECP in Congestive Heart Failure) established the clinical basis for EECP in heart failure with reduced ejection fraction. Patients showed improvements in exercise duration, quality of life scores, and NYHA functional class.
The mechanism is particularly relevant for ischemic heart failure — where reduced blood flow to the myocardium is the underlying driver. EECP's diastolic augmentation directly addresses coronary perfusion in these patients.
For patients with exercise intolerance who struggle to complete cardiac rehab, EECP offers a passive alternative that improves functional capacity without requiring active exertion.
PEECH Trial (Feldman et al., 2006). FDA-cleared for ischemic heart failure.
Long COVID & Post-Viral Vascular Syndrome
Long COVID is increasingly understood as a vascular disease. Endothelial damage, microclotting, and impaired circulation are central to the symptom picture — fatigue, brain fog, exercise intolerance, POTS-like dysautonomia, and chest symptoms.
Early observational data from EECP in long COVID patients shows improvement across all eight SF-36 quality-of-life domains. The mechanistic rationale is strong: EECP directly addresses endothelial dysfunction and improves microvascular flow.
This is an off-label use. The randomized trial evidence is limited. We tell patients this directly. For patients who have exhausted other options and are looking for something with a plausible mechanism and a favorable safety profile, EECP is worth a serious conversation.
Observational data (2022–2024). Mechanistic rationale: endothelial dysfunction, microclotting, impaired microvascular flow.
Post-Stent & Post-Bypass Symptoms
Between 20 and 40% of patients who undergo stenting or bypass surgery continue to experience angina, exercise intolerance, or reduced quality of life. This is not a failure of the procedure — it reflects the reality that stents and bypass address large-vessel obstruction, not microvascular disease or endothelial dysfunction.
EECP targets both. For post-intervention patients with persistent symptoms, EECP addresses the vascular environment that the procedure couldn't reach.
This is one of the most common presentations we see. Many of these patients were told their procedure was successful and then left to manage ongoing symptoms with medication. EECP offers a meaningful next step.
Multiple studies on persistent symptoms post-revascularization. EECP addresses microvascular disease and endothelial dysfunction not corrected by stents or bypass.
Cognitive Decline, Vascular Dementia & Alzheimer's
Vascular contributions to cognitive impairment are now recognized as central to most forms of dementia — including Alzheimer's. Reduced cerebral blood flow, endothelial dysfunction, and impaired neurovascular coupling appear years before clinical symptoms.
EECP's mechanism — improved systemic circulation, endothelial upregulation, and reduced vascular resistance — is directly relevant to this picture. Early studies show improvements in cerebral blood flow velocity and cognitive function scores.
This is an area where the evidence is promising but early. We're transparent about that. For patients with early cognitive decline or strong family history, the risk-benefit calculation is favorable given EECP's safety profile.
Studies on cerebral blood flow velocity and cognitive function. Vascular contributions to cognitive impairment (VCID) literature.
Peripheral Artery Disease & Diabetic Neuropathy
Peripheral artery disease and diabetic neuropathy share a common upstream problem: impaired blood flow to the extremities. EECP's systemic improvement in endothelial function and collateral development is relevant to both.
For PAD patients with claudication (leg pain with walking), EECP has shown improvements in walking distance and ankle-brachial index. For diabetic neuropathy, improved microvascular flow to peripheral nerves is the proposed mechanism.
These are off-label uses. Patients with active DVT, severe PAD, or leg wounds in cuff areas are not candidates. We screen carefully.
Studies on ankle-brachial index improvement and walking distance in PAD. Mechanistic rationale for diabetic neuropathy.
Erectile Dysfunction
Erectile dysfunction is now understood as a vascular disease in the majority of cases — a failure of endothelial function and blood flow to penile tissue. The same mechanism that makes EECP effective for coronary artery disease makes it relevant here.
Studies show improvements in IIEF (International Index of Erectile Function) scores following EECP treatment. The effect is most pronounced in patients with cardiovascular risk factors — the population where ED is most likely to be vascular in origin.
We discuss this directly with patients. Many men with ED and cardiovascular risk factors are treating two problems with one course of EECP.
Studies on IIEF score improvement post-EECP. Endothelial dysfunction as primary mechanism of vascular ED.
POTS & Dysautonomia
Postural orthostatic tachycardia syndrome (POTS) and related dysautonomia conditions involve impaired autonomic regulation of blood flow — particularly the failure to maintain adequate cerebral perfusion on standing.
EECP's effect on vascular tone, endothelial function, and systemic circulation is mechanistically relevant. Some patients with POTS — particularly post-COVID POTS — have shown improvement in symptoms and heart rate variability.
This is an off-label use with limited formal evidence. We discuss this honestly with patients. For those who have tried other approaches without success, EECP is worth exploring.
Observational data in post-COVID POTS. Mechanistic rationale: endothelial dysfunction, impaired vascular tone.
You don't have to be sick to benefit from better circulation.
The NCP-5's third FDA clearance — for improving VO₂ max, vasodilation, and blood flow in healthy individuals — opens EECP to a category of patients who aren't in the standard clinical picture: people who want to optimize cardiovascular function before disease develops, or who want to maintain the gains from a prior treatment course.
This is also the clearance that makes EECP relevant for:
- —Athletes and high-performers seeking cardiovascular optimization
- —Patients with family history of heart disease who want to be proactive
- —Post-treatment patients maintaining gains from a prior course
- —Healthy spouses completing treatment alongside a partner
We're transparent about what the evidence shows and what it doesn't.
Some of the conditions on this page — long COVID, dementia, POTS, Parkinson's — are off-label uses of EECP. The mechanistic rationale is strong. The observational data is promising. The randomized controlled trial evidence is limited or absent.
We tell patients this directly. We don't oversell the evidence for conditions where the evidence is early. We do think the risk-benefit calculation is favorable for most patients given EECP's safety profile — but we want patients making informed decisions, not hopeful ones.
If you want to understand the evidence for your specific condition before you commit to anything, call us. We'll walk through it honestly.
Jack Clifford's definitive patient guide — the science, the history, the politics, and the practical reality of EECP. The book I wish I'd had in that hospital bed.